Statements (52)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
5
|
| gptkbp:bfsParent |
gptkb:quetiapine
|
| gptkbp:approves |
gptkb:2004
gptkb:FDA |
| gptkbp:brand |
gptkb:Seroquel
|
| gptkbp:category |
gptkb:C
not recommended |
| gptkbp:clinical_trial |
studies on efficacy
studies on safety studies on long-term effects |
| gptkbp:contraindication |
concurrent use of certain medications
hypersensitivity to quetiapine |
| gptkbp:dosage_form |
oral
|
| gptkbp:duration |
as prescribed by a doctor
|
| gptkbp:education |
potential side effects
avoidance of alcohol importance of adherence to prescribed regimen need for regular blood tests reporting any unusual symptoms |
| gptkbp:form |
extended-release tablet
|
| gptkbp:has_ability |
50 mg
400 mg 150 mg 300 mg |
| https://www.w3.org/2000/01/rdf-schema#label |
Seroquel XR
|
| gptkbp:ingredients |
gptkb:quetiapine
|
| gptkbp:interacts_with |
CY P3 A4 inducers
CY P3 A4 inhibitors |
| gptkbp:is_atype_of |
N05 A H04
|
| gptkbp:is_monitored_by |
regular follow-up visits
|
| gptkbp:is_used_for |
treatment of schizophrenia
treatment of bipolar disorder treatment of major depressive disorder |
| gptkbp:legal_issue |
prescription only
|
| gptkbp:lifespan |
6 hours to 7 hours
|
| gptkbp:manager |
oral
|
| gptkbp:manufacturer |
gptkb:temple
|
| gptkbp:marketed_as |
gptkb:Seroquel_XR
|
| gptkbp:packaging |
gptkb:beer
|
| gptkbp:rounds |
urine
feces |
| gptkbp:side_effect |
dizziness
drowsiness constipation dry mouth weight gain |
| gptkbp:social_structure |
C21 H25 N3 O2 S
|
| gptkbp:symptoms |
anxiety
nausea irritability insomnia |